ABSK043 + glecirasib

ABSK043 + glecirasib is a combination of two investigational oral small molecule drugs being developed for the treatment of non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. **ABSK043** is a highly selective small molecule PD-L1 inhibitor developed by Abbisko Therapeutics. It works by binding to PD-L1, inducing its internalization and inhibiting the PD-1/PD-L1 interaction, thus alleviating immune suppression and enhancing T cell-mediated anti-tumor responses. **Glecirasib** (AST-24081) is a selective, covalent KRAS G12C inhibitor, irreversibly binding to the mutated cysteine residue on GDP-bound KRAS G12C, locking it in its inactive state and preventing downstream oncogenic signaling. The combination is intended to enhance anti-tumor efficacy by targeting both tumor immune evasion and oncogenic signaling pathways. The combination is being investigated in a Phase 2, open-label clinical trial in patients with KRAS G12C-mutant, locally advanced or metastatic NSCLC[1][3][5].